AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 93 min read$ISRG

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3

Original reporting
theglobeandmail.com
Published Sep 9, 2026, 1:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now? — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ISRGNeutralMed
01

Why it matters

Earnings beat and guidance suggest continued growth, but valuation remains premium; investors must weigh cost pressures versus procedural growth.

02

Market read

The earnings update is material for traders tracking med‑tech valuations and could influence sector rotation.

03

What to watch

Potential upside from single‑port platform adoption and upcoming FDA clearance for a flexible robotic endoscope.

Relevance 7/10Novelty 6/10Timing: post‑quarter 2026 earnings release

Background

The article provides a valuation‑focused analysis of Intuitive Surgical after its Q2 2026 earnings release.

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Q2 2026 results and updated guidance were disclosed for the first time, showing revenue up 19% YoY and adjusted EPS up 28% with a forward P/E of 30.26x.

Expected impact

Potential modest upside if the market re‑rates the valuation gap to peers.

Evidence & confidence

Earnings are solid and guidance is durable, yet valuation compression is limited by higher costs and competitive pressures.

Market effects

Sector

Highlights valuation disparity within the medical‑instruments sector, may prompt re‑rating of peers Medtronic and Stryker.

Regional

U.S. hospital spending outlook remains a key driver; Chinese tender volume uncertainty could affect broader med‑tech exposure.

Global

Intuitive Surgical’s global footprint makes the earnings relevant to worldwide robotic‑surgery markets.

Counterpoint

What could challenge this read

Despite earnings beat, the stock may stay overvalued given high forward P/E and cost headwinds.

Key entities

  • Company
    Intuitive Surgical

    Manufacturer of da Vinci surgical robots.

Read at source← All news

Related articles

SEP 10
$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

yahoo.com3 min
SEP 4
$ISRGMedAI 8/10

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

aol.com2 min
AUG 31
$ISRGMedAI 8/10

New da Vinci Surgical Robot Secures Marketing Approval: Entering Olympus’ Core Dominant Surgical Market

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

eu.36kr.com3 min
AUG 25
$NKELow

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

yahoo.com2 min
AUG 24
$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

yahoo.com3 min